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Case PresentatIon
A 54-year-old female patient had a his-
tory of ESRD under regular continuous au-
tonomic peritoneal dialysis (CAPD) for 6 
years. She had also a history of hypertension, 
gout, and chronic glomerulonephritis, which 
IntroduCtIon
Vision disorders are a common problem 
in end-stage renal disease (ESRD) patients. 
Most patients under regular dialysis have 
diabetes mellitus and hypertension. In these 
subjects, vision problems are commonly re-
lated to diabetic retinopathy and hyperten-
sive retinopathy.
On the contrary, drug side effects are un-
common causes of vision disorders.
In the past, aluminum (Al) overdose or 
toxicity was also considered common in 
ESRD patients. Chelating agents have been 
successfully used to treat Al-related disor-
ders. Among their side effects, there are mild 
local reactions at the injection site, anaphy-
lactic reactions, cataracts, ocular toxicity, and 
neurotoxicity.
Why Do We Describe This Case
Vision disorders are common in end-stage 
renal disease (ESRD) patients. They may 
be due to diabetic retinopathy and hyper-
tensive retinopathy. Ocular toxicity caused 
by deferoxamine is uncommon in ESRD 
patient. If this condition is not promptly 
detected, permanent blindness may occur
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Case report
abstract
A 54-year-old female patient had a history of end-stage renal disease (ESRD) under continuous 
automatic peritoneal dialysis (CAPD) therapy for 6 years. She had underlying hypertension 
history under oral hypertensives (olmesartan medoxomil). She was admitted to the ward for 
iron chelating agent therapy due to high ferritin level (5480 ng/ml). Deferoxamine 1 gram was 
prescribed with intravenous drip for 24 hours for 5 days. On the fifth day, she complained about 
vision problems, i.e. central halo pattern vision loss. A deferoxamine-related macula edema was 
diagnosed. After discontinuing the medication, her vision gradually improved. After 3 months 
of follow up, her vision disorders recovered.
Although we reduced the dose of iron chelating agent, vision side effects also occurred in this 
ESRD patient. 
This case taught us to perform a careful detection of vision problems before, during, and after 
deferoxamine therapy in order to prevent irreversible vision disorders. 
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led to chronic kidney failure. She was taking 
folic acid 5 mg 1 tablet every alternate day 
(QOD), olmesartan medoxomil 20 mg 1 tab-
let daily, and calcium acetate 1 tablet thrice 
with meal. Previously, she was given oral iron 
support 100 mg per day for 3 years due to 
chronic anemia and ESRD status. Blood 
transfusion was given 2 units per every 3 
months for 3 years. Serum iron level and 
transferrin levels were monitored every 3 
months, according to the guidelines from 
Kidney Disease Improving Global Outcomes 
(KDIGO) [1]. She wasn’t given iron tablets 
due to high iron level in the last 3 years. Blood 
transfusion was reduced to prevent further 
iron overload. We maintained hemoglobin 
level (Hb) around 8 g/dl. In the outpatient 
department, high ferritin level (5480 ng/ml 
on 27 Feb 2018) was noted. She also had 
complained about non-specific symptoms, 
like weakness and malaise. Therefore, she was 
hospitalized for iron overload therapy on 
March 2018. Table 1 reports laboratory data.
For iron overload study, hepatic iron con-
centration was not measured because not 
available in our hospital. Deferoxamine test 
was not performed because aluminum tox-
icity was rare in the current dialysis setting 
and with frequent blood transfusion therapy.
Her vital signs were as follows: body tem-
perature 36.6°C, pulse rate 76/min, blood 
pressure 136/89 mmHg. General examina-
tion was unremarkable except peritoneal 
dialysis (PD) catheter at the left lower quad-
rant of the abdomen. Neither diffuse abdom-
inal pain, nor abnormal mass were detected. 
Her vision fields were all normal because she 
could do PD exchange by herself.
We also consulted a hematologist for dos-
age of iron chelating therapy, who suggested 
to use deferoxamine 1-gram intravenous 
drip for 24 hours for 5 days.
She didn’t have any discomfort during the 
first 3 days of therapy. On the fifth day, she 
complained about vision problems, which she 
noted during PD exchange. She had already 
complained about the halo vision impairment 
on the fourth day, and color blindness was 
noted. Her visual field defect progressed. An 
ophthalmologist was consulted for the vision 
problems. After examination, macula edema 
was impressed, and it was suggested to stop 
deferoxamine therapy. The ophthalmologist 
suspected that  the visual problem was re-
lated to deferoxamine injection. Fundoscopy 
and optical coherence tomography (OCT) 
confirmed macula edema (Figures 1 and 2).
We immediately discontinued intravenous 
drip therapy and performed frequent assess-
Parameter detected level normal range
WBCs (n/L) 13,100 4000-11,000
Neutrophils (%) 84.3 55-75
PLTs (n/L) 391,000 140,000-450,000
Hb (g/dL) 8.3 11-16
Ht (%) 24.7 34-50
Serum iron (µg/dL) 116 50-175
TIBC (µg/dL) 231 255-450
Ferritin (ng/mL) 5480.8 14-165
Uric acid (mg/dL) 7.3 2.3-6.6
BUN (mg/dL) 64 8-20
Cr (mg/dL) 11 0.4-1.2
Na+ (mEq/L) 136 136-144
K+ (mEq/L) 4.2 3.5-5.1
Ca++ (mg/dL) 8.2 8.9-10.3
PO4
3- (mg/dL) 6.0 2.7-4.5
Alb (g/dL) 3.8 3.5-5.0
table I. Laboratory 
analyses performed in 
2018.
Alb = albumin;  
BUN = blood urea nitrogen;  
Cr = creatinine;  
Hb = hemoglobin;  
Ht = hematocrit;  
PLTs = platelets;  
TIBC = total iron binding 
capacity;  
WBC = white blood cells
Figure 1. Fundoscopy 
findings revealed 
irregularly increased or 
decreased background.
Figure 2. Optical 
Coherence Tomography 
(OCT) revealed 
granular hyperreflective 
deposits, that were 
detected in the 
subretinal space.
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complained about non-specific symptoms, 
like weakness and malaise. Therefore, she was 
hospitalized for iron overload therapy on 
March 2018. Table 1 reports laboratory data.
For iron overload study, hepatic iron con-
centration was not measured because not 
available in our hospital. Deferoxamine test 
was not performed because aluminum tox-
icity was rare in the current dialysis setting 
and with frequent blood transfusion therapy.
Her vital signs were as follows: body tem-
perature 36.6°C, pulse rate 76/min, blood 
pressure 136/89 mmHg. General examina-
tion was unremarkable except peritoneal 
dialysis (PD) catheter at the left lower quad-
rant of the abdomen. Neither diffuse abdom-
inal pain, nor abnormal mass were detected. 
Her vision fields were all normal because she 
could do PD exchange by herself.
We also consulted a hematologist for dos-
age of iron chelating therapy, who suggested 
to use deferoxamine 1-gram intravenous 
drip for 24 hours for 5 days.
She didn’t have any discomfort during the 
first 3 days of therapy. On the fifth day, she 
complained about vision problems, which she 
noted during PD exchange. She had already 
complained about the halo vision impairment 
on the fourth day, and color blindness was 
noted. Her visual field defect progressed. An 
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problems. After examination, macula edema 
was impressed, and it was suggested to stop 
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suspected that  the visual problem was re-
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Hb = hemoglobin;  
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Figure 1. Fundoscopy 
findings revealed 
irregularly increased or 
decreased background.
Figure 2. Optical 
Coherence Tomography 
(OCT) revealed 
granular hyperreflective 
deposits, that were 
detected in the 
subretinal space.
ments of her vision condition during hospi-
talization. Her vision condition improved 
before discharge, when she could again ex-
change her PD dialysate fluid by herself. 
Follow-up visits were arranged by ophthal-
mologist. OCT was done one month after 
discharge, then 5 months after discharge. 
The macula edema of both eyes recovered, 
and vision condition improved.
dIsCussIon
There is a myriad of diseases that affect 
both the eyes and kidneys (oculorenal syn-
dromes) [2]. In our clinical practice, half of 
dialysis patients have underlying diabetes 
mellitus, mainly accompanied by diabetes 
retinopathy and glaucoma [3]. Hyperten-
sive retinopathy may also result in vision 
disorders. Vision problems in dialysis may 
also be due to the retinal vessel’s stenosis 
or occlusion. In addition, the side effects of 
medications should be considered as one of 
the causes of vision disorders.
What Should the Clinician Ask Him/Herself or the Patient?
 y First, the sudden onset of vision problems should suggest to investigate blood pressure, 
trauma, or progress of vision loss
 y If there is no obvious cause, the specialist should be consulted
 y Check the medications that may have resulted in the sudden vision problem
 y If the problem is due to medication, stop it immediately and perform a proper follow-up
Among the ocular problems in chronic 
kidney disease and hemodialysis there are:
 y glaucoma;
 y metastasis calcification of cornea and 
conjunctiva;
 y band keratopathy;
 y superior limbic keratoconjunctivitis;
 y cataracts;
 y retinal detachment;
 y macular leakage;
 y retinal hemorrhage;
 y drug toxicity; and
 y optic neuropathy (anterior ischemic neu-
ropathy or uremic optic neuropathy) [3].
Malignant hypertension can result in 
acute, substantial loss of vision owing to 
ischemic optic neuropathy and severe mac-
ulopathy. This condition may be checked 
through fundus examination [4], and an ag-
gressive control of blood pressure results in 
a gradually recover of retinopathy.
Diabetic retinopathy is present in almost 
all type 1 diabetes patients with nephropa-
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 y rheumatoid arthritis;
 y renal failure; and
 y metabolic encephalopathy.
For visual testing, functional testing 
should include electrophysiology, visual 
field, and microperimetry. For structural 
abnormalities, fluorescein angiography and 
OCT can be used [3]. Fundus autofluores-
cence imaging is a pre-requisite for identify-
ing specific high-risk characteristics. OCT 
may help detecting extent and location of 
different retinal changes. DFO retinopathy 
is always bilateral, but asymmetrical in fun-
dus autofluorescence finding. It may have 
different patterns [12]:
 y minimal change pattern (56%);
 y focal pattern (17%);
 y patchy pattern (16%); and
 y speckled pattern (11%).
There is no association between pattern 
type and duration of DFO treatment. The 
area of increased fundus autofluorescence 
signal indicated diffuse accumulation of 
autofluorescent fluorophores within a thick-
ened retinal pigment epithelium-Bruch 
membrane complex or also focal accumu-
lation of autofluorescent outer segment-
derived retinoid products in the subretinal 
space. In early stage of disease, OCT usu-
ally shows only focal thickenings or bumps 
of the retinal pigment epithelium, resem-
bling basal laminar drusen. As the disease 
progresses, the coalescence of these bumps 
of pigmented material appears on OCT as 
thick and hyperreflective dome-shaped le-
sions that disrupts the architecture of the 
overlying outer retinal layers. In advanced 
stages, frank retinal pigment epithelium and 
photoreceptors atrophy may develop in the 
macula, as well as migration of hyperreflec-
tive subretinal deposits towards the outer 
plexiform layer interrupting the overlying 
external limiting membrane [12].
There is no available treatment for patients 
with DFO retinopathy other than drug dis-
continuation or dose reduction. In one re-
view article, DFO administration dose has 
not exceeded 50 mg/kg of body weight in 
patient with iron overload [3].
In our case, despite the fact that the dose 
of DFO did not exceed 50 mg/kg, vision 
problems occurred. She was alert and could 
explain her complaint well. But in elderly or 
bed-ridden status patients, vision problem 
may go undetected. In ESRD patients, fre-
quent blood transfusions and iron therapy 
(per os and i.v.) are performed. Therefore, it 
thy, whereas only 50-60% of patients with 
type 2 diabetes with proteinuria have reti-
nopathy [5]. Blindness due to proliferative 
retinopathy or maculopathy is approximately 
five times more frequent in type 1 and type 
2 diabetic patients with retinopathy than in 
normoalbuminuric patients.
Deferoxamine (DFO) is one of the medi-
cations used to treat aluminum intoxication, 
even though in the current practice it is not 
very frequent, while iron overload is more 
common. DFO chelates aluminum in dialy-
sis patients, and iron in dialysis or hemosid-
erosis patients. It has high affinity for ferric 
iron, thus removing iron from hemosiderin, 
ferritin, and transferrin.
In peritoneal dialysis patients, DFO can 
be given by intravenously or intraperitoneal 
route, resulting in similar iron clearance de-
grees. Iron-deferoxamine complex is a water-
soluble middle molecule range, thus it can 
clear more efficiently during peritoneal dialy-
sis. It may have several side effects: hypoten-
sion, anaphylaxis, and hearing disorders. This 
medication has been associated with retinal 
toxicity in some case reports [3,6-8]. Ocular 
toxicity can occur in patients with normal re-
nal function and dialysis patients. Typically, 
patients complain of decreased visual acuity, 
color blindness (yellow-blue axis), or night 
blindness. Although these effects are often 
reversible, some patients experience persis-
tent visual impairment secondary to DFO 
administration [3].
The mechanism of retinal damage is un-
known, but studies have shown pigmentary 
retinal degeneration [6,7]. Some articles 
reported optic neuritis and/or macula in-
volvement [9].
Decreased visual acuity and abnormal 
pigmentation were first recognized in two 
thalassemic patients [10]. A study on dialysis 
population treated with DFO showed that 
33% of patients have macular changes, that 
involved peri-macular pigmented deposits, 
and these findings did not have a signifi-
cant correlation with the total administered 
dose or the method of DFO administration 
[11]. While the incidence of DFO-induced 
ocular toxicity in patients with normal renal 
function varies between 0% and 4%, in he-
modialysis patients the incidence is higher, 
affecting 17% to 73% of subjects. Most, but 
not all, ocular toxicities may resolve.
Risk factors for visual loss in DFO reti-
nopathy includes [3]:
 y blood-retinal barrier breakdown associ-
ated with diabetes;
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with frequent blood transfusions or long-
term iron therapy. However, sight-threating 
retinopathy may occur after DFO therapy. 
There is no gold standard identification of 
ocular toxicity in DFO therapy. Among the 
patients at highest risk, there are those af-
fected by diabetes, renal failure, rheumatoid 
arthritis, and metabolic encephalopathy. In 
renal failure patients under regular hemo-
dialysis or peritoneal dialysis, iron overload 
can occur due to iron therapy and frequent 
blood transfusions. Aluminum intoxication 
can also be effectively treated with DFO. 
Most dialysis patients suffer from asthenia, 
weakness, diabetic, and other elderly-related 
disorders, among which poor vision.
Clinicians need to keep in mind the pos-
sible adverse effects of DFO therapy, in order 
to avoid permanent visual loss.
Key Points
 y Visual problem is not uncommon in ESRD patients
 y Iron overload is also common in ESRD patient due to iron supplement and frequent blood 
transfusion for chronic anemia
 y Early detection and daily assessment of vision problems after DFO are needed to prevent 
permanent damages to the retina
 y After discontinuing the medication, visual problems will resolve gradually
 y Afterwards, follow-up with OCT visits should be performed for at least one year
 y Fundus autofluorescence imaging is a pre-requisite for identifying specific high-risk char-
acteristics. OCT may have clinical usefulness in detecting extent and location of different 
retinal changes
is necessary to monitor the patient vision 
condition, after the injection of DFO. If 
vision disorders are not noticed early, a per-
manent damage of retina may occur, as long 
as permanent vision loss.
In addition, before starting iron chelation 
therapy, clinicians should consider other 
markers of iron overload together with fer-
ritin (liver iron concentration, transferrin 
saturation, deferoxamine test) in order to 
minimize the toxic side effects due to iron 
chelators.
ConClusIon
In conclusion, deferoxamine is the most 
important drug for the treatment of hemo-
siderosis secondary to long-term treatment 
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